Loading
STX-1911 is an experimental bispecific CyTAC with antibody-drug conjugate platform antibody from Solu Therapeutics, in preclinical development for prostate cancer.
STX-1911 is a bispecific CyTAC with antibody-drug conjugate platform antibody from Solu Therapeutics. A bispecific CyTAC targeting two tumour antigens highly expressed in prostate cancer, using the company's antibody-drug conjugate platform antibody. Its furthest stage is preclinical development, for prostate cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Discovery stage per pipeline page. It has not been shown to work in people.
A bispecific CyTAC targeting two tumour antigens highly expressed in prostate cancer, using the company's antibody-drug conjugate platform antibody.
1.STX-1911's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"STX-1911" OR ABSTRACT:"STX-1911") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STX-1911, not a curated reading list.
Shares Solu Therapeutics and the tag pipeline.
Shares Solu Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/